Acrivon Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Inform ation.
Rule 10b5-1 Trading Plans
The adoption or termination of contracts, instructions or written plans for the potential purchase or sale of our securities by our Section 16 officers and directors for the three months ended June 30, 2024, each of which is intended to satisfy the affirmative defense of Rule 10b5-1(c) ("Rule 10b5-1 Plan"), were as follows:
| Name | Title | Action | Date Adopted | Expiration Date | Maximum Number of Securities to Be Sold |
|---|---|---|---|---|---|
| Peter Blume-Jensen | CEO, President, Chairman of the board | Adoption | 05/28/2024 | 09/20/2025 | 440,000 |
| Kristina Masson | EVP Business Operations, Director | Adoption | 05/28/2024 | 09/20/2025 | 120,000 |
| Eric Devroe | Chief Operating Officer | Adoption | 05/29/2024 | 09/20/2025 | 20,275 |
| Jean-Marie Cuillerot | Chief Medical Officer | Adoption | 06/12/2024 | 09/20/2025 | 4,800 |
| Katharine Peterson | Chief Accounting Officer | Adoption | 06/13/2024 | 09/20/2025 | 19,000 |
| Mary-Alice Miller | Chief Legal Officer | Adoption | 06/14/2024 | 09/20/2025 | 10,582 |
| Erick Gamelin | Chief Development Officer | Adoption | 06/18/2024 | 09/20/2025 | 32,600 |
The above potential sales are contingent on the market price of the Company’s common stock being higher than certain minimum threshold prices specified in each 10b5-1 Plan.
Other than as described above, to date June 30, 2024, none of our directors or Section 16 reporting officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of the SEC's Regulation S-K).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.